Medicare Finally Covers Obesity Drugs, But Almost No One Knows It

A historic change flying under the radar

Since July 1, 2026, millions of older Americans enrolled in Medicare have had access, for the first time, to obesity drugs covered by the public program. It's a victory patients, doctors, and advocacy groups for people with obesity have been waiting years for. Yet this major breakthrough seems to have gone almost unnoticed.

According to a survey conducted by the Obesity Care Advocacy Network among more than 2,100 adults aged 65 and older in late March 2026, 82% of older adults did not know that Medicare was about to cover these treatments. The figure was 79% among Republican respondents and 84% among Democrats, a small gap showing this ignorance crosses partisan lines with ease.

The program, in brief

This new mechanism is called the Medicare GLP-1 Bridge, a temporary program set up by the Centers for Medicare & Medicaid Services (CMS). It lets eligible beneficiaries obtain certain GLP-1-based drugs for a fixed monthly copay of $50, a trivial sum compared to the usual price of these treatments, which can exceed $1,000 a month without insurance.

The program covers three specific drugs: Foundayo in tablet form, Wegovy as an injection or tablet, and Zepbound only in KwikPen injector form, excluding single-dose vials. It is a time-limited demonstration, scheduled to run through December 31, 2027.

Precise but broad criteria

To be eligible, a beneficiary must be 18 or older and meet one of the following criteria at the time treatment begins: a body mass index (BMI) of 35 or higher, or a BMI between 30 and 34.99 combined with a condition such as heart failure with preserved ejection fraction, uncontrolled hypertension, stage 3a or higher chronic kidney disease, prediabetes, a history of heart attack or stroke, or symptomatic peripheral artery disease.

People with a BMI between 27 and 29.99 may also qualify if they present one of these same at-risk conditions. It's a relatively wide entry point, but it still requires a rigorous medical evaluation and a properly issued prescription.

The exclusions that complicate the picture

Some beneficiaries won't be able to take advantage of the program. Those already receiving coverage for a GLP-1 drug under their Part D plan for a use already covered by Medicare — such as type 2 diabetes, cardiovascular risk reduction, or sleep apnea — are not eligible for this new obesity-specific coverage. The system therefore remains complex to navigate, even for the best-informed patients.

The treating physician must send a prescription to the pharmacy, complete a prior authorization if required, and certify that the patient is following a lifestyle program focused on diet and exercise. This authorization remains valid through December 31, 2027, including renewals and dosage changes.

Minimal government communication

Several doctors and experts interviewed by American media noted surprisingly limited publicity from CMS ahead of the July 1 launch. An agency official explained that beneficiaries are "most likely to act" once a benefit is actually available to them, justifying heavier promotion after launch rather than before, "in the interest of responsible stewardship of public funds."

This logic, while defensible on budgetary grounds, leaves an information vacuum precisely when patients would need clarity the most. Health policy researcher Kenneth Thorpe noted that making the program known, and who qualifies for it, will likely be one of the biggest challenges of this rollout.

The manufacturers' silence also surprises

What stands out most is the contrast with the usual marketing aggressiveness of Novo Nordisk and Eli Lilly, the two manufacturers whose products are covered by the program. These companies have spent enormous sums advertising their obesity drugs: nearly $500 million for Novo over the first nine months of 2025 for Wegovy and Ozempic, and just over $200 million for Lilly for Zepbound and Mounjaro over the same period, according to data from ad-tracking firm MediaRadar reported by Reuters.

Yet for the Bridge program's launch, these same companies have stayed surprisingly quiet. A Novo executive said promotion was mostly happening through targeted mentions on social media and the company's website, without a television campaign. Lilly's president of global customer capabilities, Ilya Yuffa, explained the company generally prefers to prepare doctors first before building broader consumer awareness, to avoid friction between patients and physicians.

A lack of information that worries practitioners

Dr. Shauna Levy summed up the problem in simple terms: she has seen very little information aimed at the public, and she expects many patients will simply have no knowledge of the Bridge program at all. In her view, this means patients will take even longer to discover it exists, and then to check whether they qualify.

That delay is not trivial for a population of older patients, often already juggling multiple chronic conditions and a health system that's already hard to navigate. Every week of delay in discovering this coverage can translate into months of delayed treatment for people who genuinely need it.

The financial analyst shares his surprise

Analyst David Risinger also expressed surprise at the lack of advertising from Lilly and Novo to prepare older adults to get their prescriptions. This observation, coming from an industry watcher used to tracking these giants' commercial strategies, reinforces the idea that this discretion is probably not accidental.

A slower rollout could also give doctors, pharmacies, and CMS time to prepare before a potentially very large number of beneficiaries start requesting these treatments, an understandable logistical rationale that nonetheless leaves patients in the dark in the meantime.

A copay that escapes the usual rules

The $50 monthly copay works differently from standard Medicare rules. Because a separate program covers this drug, that amount does not count toward the annual deductible of the drug plan, does not appear on the Part D plan's explanation of benefits, does not appear on the Medicare summary notice either, cannot be reduced through programs like Extra Help, and cannot be spread over several months through Medicare's prescription drug payment plan.

It's a peculiar cost structure that can confuse patients used to Medicare's usual mechanisms, further underscoring the importance of clear communication from the start, rather than after the fact.

Enrollment isn't automatic

Unlike other forms of Medicare coverage, enrollment in the Bridge program is not automatic. Patients must meet the eligibility criteria, obtain a prescription, and receive approval for a prior authorization through CMS before coverage begins. This extra step, while necessary to control the costs of a public program, adds yet another barrier for patients who are already poorly informed of its existence.

Because the program is administered directly by CMS rather than by the Part D plans themselves, private insurers have no role to play in educating beneficiaries about this new coverage, which may partly explain why information is struggling to reach patients effectively.

A hard-won victory after years of gridlock

This coverage represents the culmination of several years of pressure from patients, doctors, and advocacy groups demanding that Medicare recognize obesity as a chronic disease deserving reimbursed drug treatment, on par with diabetes or hypertension. For a long time, GLP-1 weight-loss drugs were excluded from federal coverage, forcing patients to pay out of pocket, often unaffordable amounts.

The fact that the government chose the path of a temporary demonstration program, rather than permanent and automatic coverage, shows just how politically and fiscally fragile this breakthrough remains, subject to reassessment by the end of 2027.

The budgetary weight of an aging population

The potential cost of this expanded coverage to federal finances partly explains CMS's caution. With millions of beneficiaries potentially eligible under relatively broad BMI criteria, the program could represent a considerable public expense if uptake exceeds initial projections, which helps explain, without necessarily excusing, the restraint observed in promoting the program so far.

This tension between expanded access to care and control of public costs will remain at the heart of the debate over this program's future long after its scheduled expiration date.

Concrete steps to take

For Medicare beneficiaries who think they might be eligible, the first step is to speak directly with their treating physician about potential eligibility for the Bridge program, rather than waiting for official communication that might be slow to arrive. Patients must be enrolled in a Part D plan, whether standalone or bundled into a Medicare Advantage plan, to qualify for this new coverage.

Those who receive a letter confirming their GLP-1 drug is covered under the Bridge program should hold onto it carefully, since it confirms their eligibility for the duration of the program, through December 31, 2027, barring a treatment change.

The importance of asking the right questions

Pharmacies may ask for the beneficiary's Medicare number or the last four digits of their Social Security number to process the prescription. Patients who suspect fraud can contact the 1-800-MEDICARE line directly. In a system where official information remains scarce, these practical details take on outsized importance in avoiding unpleasant administrative surprises.

It is precisely these technical details, absent from major advertising campaigns, that should be hammered home by family doctors, community pharmacists, and senior advocacy organizations in the months ahead.

A recurring problem in federal programs

This is not the first time a federal health program has struggled to reach its target audience due to inadequate communication. Health policy experts point out that similar mechanisms, such as certain coverage expansions for vaccines or preventive screenings, saw disappointing adoption rates in their early years, simply because beneficiaries didn't know they existed or that they qualified.

The pattern repeats itself here with the Bridge program: generous design on paper, but execution that relies largely on word-of-mouth from doctors rather than a structured information campaign from day one.

The crucial role of community organizations

In this vacuum of official communication, senior advocacy groups and obesity patient associations are trying to bridge the gap by getting information directly to their members. These efforts, while useful, do not replace a coordinated national campaign led by the federal government itself.

Without a concerted effort involving family doctors, pharmacists, community organizations, and government agencies, the risk remains that this program will primarily benefit patients already best connected to information, rather than the entire population it should serve.

A mixed record

The launch of the Medicare GLP-1 Bridge program undeniably represents a concrete breakthrough for millions of older Americans dealing with obesity and its complications, finally giving them access to treatments previously out of financial reach for most of them. It is a well-earned victory after years of mobilization by patients and public-health advocates.

But this victory risks remaining largely theoretical for a good portion of the target population if the information gap persists. A program that 82% of those affected still didn't know about just weeks before its launch cannot claim to fully fulfill its social mission, no matter how well designed it is technically.

The test of the coming months

The real measure of this program's success will play out in the months after its launch: will the information eventually reach the patients who need it most, through their doctors and pharmacists, or will this expanded coverage remain a well-kept secret until it expires in 2027? The upcoming promotional campaigns announced by CMS and the manufacturers after launch will be worth watching closely.

What is certain is that the best health policy in the world is worthless if the people it's meant to serve don't know it exists.

By Maxime Marquette, columnist

Editorial stance

I am not a journalist but a columnist and analyst. My expertise lies in observing and analysing the geopolitical, economic and strategic dynamics that shape our world. My work is to take political strategies apart, to understand global economic movements, to put the decisions of international actors in context and to offer analytical perspectives on the changes that are redefining our societies.

I do not claim the cold objectivity of traditional journalism, which stops at reporting facts. I claim analytical clarity, rigorous interpretation and a deep understanding of the complex issues that concern us all. My role is to give meaning to the facts, to place them in their historical and strategic context, and to offer a critical reading of events.

Method and sources

This text keeps the basic distinction between verified facts and interpretive analysis. The rule never changes: a factual claim is published only when a verifiable source supports it, and the sources this article actually used are listed under Sources, never here.

Primary source families used by the publication, when the story has them: official statements from governments and international institutions, public statements by political leaders, reports from intergovernmental organisations, dispatches from recognised international news agencies.

Secondary source families: specialised publications, internationally recognised news media, analyses from established research institutions, reports from industry organisations.

When an article cites statistical, economic or geopolitical data, it comes from the institutions that produce it (intergovernmental organisations, central banks, national statistics offices), and the exact institution is named under Sources.

Nature of the analysis

The analyses, interpretations and perspectives in the analytical sections of this article are a critical, contextual synthesis based on the information available, the trends observed and the expert comments cited in the sources consulted.

My role is to interpret these facts, to set them in the context of today's geopolitical and economic dynamics, and to give them a coherent meaning within the larger story of the changes shaping our time. These analyses reflect expertise built through continuous observation of international affairs and an understanding of the strategic mechanisms that drive global actors.

This article describes a documented state of affairs on its publication date, not a prediction: later developments may shift its outlook. No update is promised in advance; when an article is corrected or completed, the change is dated in the text.